This site uses cookies to ensure the best viewing experience for our readers.
CTech's Monday Roundup of Israeli Tech News

CTech's Monday Roundup of Israeli Tech News

Spyware firm NSO in talks to acquire Israeli predictive analytics company Fifth Dimension; Crypto-mining outfit Bitfarms files a preliminary prospectus in Ontario

CTech | 17:38, 12.11.18
Spyware firm NSO in talks to acquire Israeli predictive analytics company Fifth Dimension. Israel-based Fifth Dimension is chaired by Benny Gantz, former chief of staff for the Israeli military. Former deputy head of the Mossad Ram Ben-Barak is on the company's advisory board. Read more

NSO co-founder Omri Lavie. Photo: Vardi Kahana NSO co-founder Omri Lavie. Photo: Vardi Kahana NSO co-founder Omri Lavie. Photo: Vardi Kahana

Crypto-mining outfit Bitfarms files a preliminary prospectus in Ontario. The Tel Aviv-listed company submitted a prospectus to the Ontario Securities Commission on Friday via its Canadian private subsidiary. Read more 

Chinese investment in Israeli tech is growing, a report says. More Chinese money is flowing into Israeli tech initiatives each year, according to a new report by Tel Aviv-based research firm IVC Research Center. Read more

Opinion | Escaping the trap of the valuation cap. Raising money through a convertible round could be a good idea if you believe that your startup’s valuation is due to go up. Just don’t lose sight of the valuation cap, writes lawyer and entrepreneur Zachi Zach. Read more  

Sleep disorder treatment company Nyxoah raises 15 million euros. Nyxoah develops a medical device for the treatment of Obstructive Sleep Apnea (OSA), a sleep disorder characterized by repeated shallow or paused breathing during sleep. Read more

Technion awarded $2.7 million government grant to establish a new innovation center. The Technion is an engineering and science university located in the northern Israeli city of Haifa, ranked 77th in the Shanghai Ranking. Read more

Israeli and French biotech companies partner to fight diabetes with a bio-artificial pancreas. Israel-based Kadimastem and France-headquartered Defymed will receive a grant of around $1.5 million from the European Commission's Eurostars program to develop the technology to treat type 1 diabetes. Read more
share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS